Clinical Research
FDA
Approves Aventis' Taxotere for First-line Treatment of NSCLC
(Aventis)
Press release announcing FDA approval of Taxotere as first-line
therapy, in combination with cisplatin, in NSCLC patients with unresectable
locally advanced or metastatic disease who have not had prior chemotherapy.
Discusses the randomized trial on which the FDA approval was based. [12/02]
Neoadjuvant
Docetaxel (Taxotere) Improves Life Expectancy in Locally
Advanced Lung Cancer (Doctor's Guide)
Reports research presented at the 9th World Congress on Lung Cancer
(September 2000) that showed docetaxel (Taxotere) used as neoadjuvant
therapy improves survival over local treatment alone in patients with
locally advanced NSCLC. [9/00]
Taxotere Monotherapy
Increases Survival in Lung Cancer Patients (Doctor's
Guide)
Summarizes research presented at the 10th meeting of the European Congress
of Clinical Oncology (ECCO) that showed monotherapy with Taxotere (docetaxel)
to be an effective first-line chemotherapy treatment for patients with
advanced non-small cell lung cancer. [9/99]
Taxotere
(Docetaxel) - Recent MEDLINE Abstracts (PubMed)
Prospective
Randomized Trial of Docetaxel Versus Best Supportive Care in
Patients with NSCLC Previously Treated with Platinum-based Chemotherapy
(Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (May
2000) reporting results of a study that found treatment with docetaxel
is associated with significant prolongation of survival when compared
to best supportive care in patients with NSCLC who had previously been
treated with platinum-based chemotherapy. [5/00]
Consolidation
Docetaxel After Chemoradiotherapy Encouraging in NSCLC (Doctor's
Guide)
Reports on a study published in the May 15, 2003 issue of the Journal
of Clinical Oncology that found the use of docetaxel (Taxotere) after
cisplatin/etoposide plus radiotherapy produces high survival rates in
patients with Stage IIIB NSCLC. [5/03]
Randomized
Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide In
Patients with Advanced NSCLC Previously Treated with Platinum Containing
Chemotherapy Regimens (Journal of Clinical Oncology)
Abstract of a study published in the June 2000 issue of the Journal
of Clinical Oncology that found, in a randomized trial,
that docetaxel (75 mg/m2) every 3 weeks can offer clinically meaningful
benefit to patients with advanced NSCLC whose disease has relapsed or
progressed after platinum-based chemotherapy.
[6/00]
Taxotere
(Docetaxel) for Lung Cancer (Aventis Pharmaceuticals)
Manufacturer's website offers general information, including a list of
frequently-asked-questions about Taxotere.
Taxotere
(Docetaxel) - Clinical Trials (ClinicalTrials.gov)
Side Effects
Taxotere
(Docetaxel) (CancerBACUP)
Factsheet describes Taxotere (also known as Docetaxel), how it is given
and some of its possible side effects. [11/02]
Taxotere (Docetaxel)
(Aventis)
Describes Taxotere (also known as Docetaxel), how it works and what side
effects to expect during and after treatment.
Docetaxel (Taxotere) & Gemcitabine (Gemzar)
Taxotere
(Docetaxel) Plus Gemzar (Gemcitabine) Doubles Anti-Tumor Effect
in Relapsed Lung Cancer (Doctor's Guide)
Reports that the combination of weekly Gemzar (Gemcitabine) and monthly
Taxotere (Docetaxel) is active and safe in patients with advanced NSCLC
who have failed prior chemotherapy according to the results of a Phase
II trial presented at ASCO 2000. Notes that durable responses were observed
at all disease sites and in cancers refractory to prior platinum therapy.
[5/00]
Docetaxel (Taxotere) and Vinorelbine
(Navelbine)
Phase
II Trial of Docetaxel and Vinorelbine in Patients with Advanced
Non-Small Cell Lung Cancer (Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (March
2000) reporting the results of a study that found docetaxel and vinorelbine,
both given every two weeks, is a highly active combination for the treatment
of advanced NSCLC. [3/00]
Docetaxel (Taxotere)
and Platinum (Cisplatin or Carboplatin)
Phase
III Study (TAX 326) of Docetaxel-Cisplatin and Docetaxel-Carboplatin vs.
Vinorelbine (Navelbine)-Cisplatin for First-line Treatment of Advanced/Metastatic
NSCLC: Analyses in Elderly Patients (ASCO)
Study results presented previously demonstrated that patients treated
with docetaxel-cisplatin had favorable response and survival outcomes
compared with vinorelbine-cisplatin treated patients. Both docetaxel-carboplatin
and docetaxel-cisplatin were better tolerated and provided patients with
consistently improved quality of life compared with vinorelbine-cisplatin.
The analyses presented at the 2003 ASCO annual meeting addressed the question
of whether elderly patients (greater or equal to 65 years) with advanced
NSCLC should be treated with platinum doublets. The study concluded that
a docetaxel-platinum combination is an active first-line treatment option
with a favorable benefit/risk profile for elderly patients with advanced/metastatic
NSCLC. [6/03]
|
